Trial Profile
A phase III study comparing nivolumab with nivolumab plus docetaxel in patients with previously treated advanced non-small-cell lung cancer: a randomized phase II/III trial(TORG1630)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 31 Aug 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms CONDUCT study; TORG1630
- 18 Aug 2022 Status changed from active, no longer recruiting to completed according to results published in the Clinical Cancer Research.
- 18 Aug 2022 Results published in the Clinical Cancer Research
- 07 Jun 2022 Primary endpoint (Phase III: Overall survival) has been met, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.